Protagenic Therapeutics Stock Fundamentals
| PTIX Stock | USD 0.65 0.04 6.56% |
Protagenic Therapeutics fundamentals help investors to digest information that contributes to Protagenic Therapeutics' financial success or failures. It also enables traders to predict the movement of Protagenic Stock. The fundamental analysis module provides a way to measure Protagenic Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protagenic Therapeutics stock.
At this time, Protagenic Therapeutics' Total Operating Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 3.5 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 26.8 K in 2024. Protagenic | Select Account or Indicator |
Protagenic Therapeutics Company Return On Equity Analysis
Protagenic Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Protagenic Therapeutics Return On Equity | -2.06 |
Most of Protagenic Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protagenic Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Protagenic Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Protagenic Therapeutics has a Return On Equity of -2.0636. This is 91.39% lower than that of the Biotechnology sector and 94.34% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Protagenic Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Protagenic Therapeutics's current stock value. Our valuation model uses many indicators to compare Protagenic Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Protagenic Therapeutics competition to find correlations between indicators driving Protagenic Therapeutics's intrinsic value. More Info.Protagenic Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Protagenic Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Protagenic Therapeutics' earnings, one of the primary drivers of an investment's value.Protagenic Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protagenic Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics of similar companies.Protagenic Therapeutics is currently under evaluation in return on equity category among its peers.
Protagenic Fundamentals
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.9 | ||||
| Current Valuation | (721.57 K) | ||||
| Shares Outstanding | 6.79 M | ||||
| Shares Owned By Insiders | 14.24 % | ||||
| Shares Owned By Institutions | 5.76 % | ||||
| Number Of Shares Shorted | 89.12 K | ||||
| Price To Earning | 9.43 X | ||||
| Price To Book | 5.75 X | ||||
| EBITDA | (4.5 M) | ||||
| Net Income | (5 M) | ||||
| Cash And Equivalents | 8.87 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 655.25 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 19.47 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (3.7 M) | ||||
| Short Ratio | 1.33 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 4.0 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 4.04 M | ||||
| Total Asset | 4.32 M | ||||
| Retained Earnings | (30.78 M) | ||||
| Working Capital | 3.54 M | ||||
| Current Asset | 3.75 M | ||||
| Current Liabilities | 736 K | ||||
| Net Asset | 4.32 M |
About Protagenic Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protagenic Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagenic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagenic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | (359.19) | (341.23) | |
| Cost Of Revenue | 28.2 K | 26.8 K | |
| Stock Based Compensation To Revenue | 0.03 | 0.03 | |
| Sales General And Administrative To Revenue | 0.20 | 0.19 | |
| Revenue Per Share | 353.2 K | 376.4 K | |
| Ebit Per Revenue | (0.64) | (0.67) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.